Drug Trial Radar · NCT03829410
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
Last checked: Nov 19, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Jun 24, 2019
Primary completion
Jan 29, 2024
Study completion Jan 29, 2024
Sponsor
- Lead sponsor
- Cardiff OncologyIndustry
- Sponsor type
- Industry
- First posted
- Feb 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line treatment in adult participants who have metastatic colorectal cancer with a KRAS mutation. Participants must have histologically confirmed metastatic and unresectable disease, and previously failed treatment or be intolerant to fluoropyrimidine and oxaliplatin with or without bevacizumab.
Conditions
- Metastatic Colorectal Cancer
- KRAS Gene Mutation
Interventions
OnvansertibDrug
Onvansertib orally.
BevacizumabBiological
Bevacizumab intravenously.
FOLFIRIDrug
FOLFIRI intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Up to Day 28
- Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to a maximum of 81 weeks
- All-Treated Analysis Set: Objective Response Rate (ORR)Time frame: Up to a maximum of 131 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center
Phoenix, Arizona
CARTI Cancer Center
Little Rock, Arkansas
USC Norris Comprehensive Cancer Center
Los Angeles, California
Mayo Clinic Florida
Jacksonville, Florida
University of Kansas Medical Center Research Institute
Kansas City, Kansas
Mayo Clinic Rochester
Rochester, Minnesota
Inova Schar Cancer Institute
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.